**Revenue from the pharmaceutical industry:** approximately 70%
**Revenue from the medical technology sector:** approximately 20%
**Revenue from the healthcare services sector:** approximately 10%

**TOP 3 markets:**
1. **China:** approximately 60%
2. **USA:** approximately 20%
3. **Europe:** approximately 15%

China National Medicines Corporation Ltd. generates the majority of its revenue from the pharmaceutical industry, attributed to its strong position in the manufacturing and distribution of medications. The medical technology and healthcare services sectors complement the portfolio and also contribute significantly to the revenue.

Geographically, China is the primary market, which is not surprising as the company is headquartered there and benefits from the large population and increasing demand for healthcare products. The USA and Europe are also important markets served through strategic partnerships and product exports.

**Production Sites:** Mainly in China

China National Medicines Corporation Ltd. produces the majority of its products within China. The company is heavily involved in the manufacturing and distribution of pharmaceutical products and leverages the country's extensive industrial infrastructure to maximize its production capacities.

By producing in China, the company can benefit from comparatively low production costs and proximity to one of the world's largest pharmaceutical markets. However, it is also possible that the company may diversify its production sites in the future to better meet global market demands.

**Revenue Growth:** Estimated 8-10% annually (2026)

China National Medicines Corporation Ltd. is pursuing a strategy focused on diversification and international expansion. The company plans to expand its product range in the pharmaceutical products and services sector to meet the growing demand in the healthcare industry.

Another key focus is on tapping into new markets outside of China. Through strategic partnerships and acquisitions, the company aims to strengthen its presence in Asia and other international markets.

In addition, China National Medicines Corporation is investing in research and development to develop innovative drugs and healthcare solutions. This is intended not only to expand the product offering but also to enhance competitiveness on a global scale.

**Main Imported Raw Materials:** Active Pharmaceutical Ingredients (APIs), Chemicals for Drug Manufacturing

**Main Supplier Countries:** India, Germany, USA

China National Medicines Corporation Ltd. mainly imports active pharmaceutical ingredients (APIs) and special chemicals required for drug manufacturing. India is a significant supplier of APIs as the country is one of the largest producers of these substances worldwide. Germany and the USA also supply high-quality chemicals and pharmaceutical products needed in production.

This import strategy enables the company to produce high-quality medicines while optimizing production costs by sourcing raw materials from countries with competitive prices.

**Market Share in China:** 8% (estimated, 2025)
**R&D Expenses:** 5% of revenue (2025)
**Net Profit Margin:** 6.2% (2025)

China National Medicines Corporation Ltd. (SHSE:600511) has a significant competitive advantage due to its strong market presence in China. With an estimated market share of 8% in 2025, the company positions itself as one of the leading players in the Chinese pharmaceutical market.

Another advantage is the continuous investment in research and development, accounting for 5% of revenue. These investments enable the company to develop innovative products and differentiate itself from the competition.

The net profit margin of 6.2% in 2025 demonstrates solid profitability, indicating efficient operations and cost-effectiveness. These factors together strengthen the company's competitive position in the market.

**Institutional Investor Share:** Estimated at around 30-40% (based on typical industry values for large Chinese companies)

**Insider Trades:** No specific data available (as of 2026)

The institutional investor share in large Chinese companies like China National Medicines Corporation Ltd. typically ranges between 30-40%. This reflects the interest of investment funds and other major financial institutions that invest in stable and high-growth companies.

Insider trades are often harder to track, especially for Chinese companies, as transparency and reporting in this area can vary. There is no specific current data for 2026, but it is important to regularly monitor corporate reports and stock exchange announcements to stay informed about such activities.

**Market share of China National Medicines Corporation Ltd.:** Estimated 5-7% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** Estimated 15-20%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** Estimated 10-12%
3. **China Resources Pharmaceutical Group Ltd.:** Estimated 8-10%
4. **CSPC Pharmaceutical Group Ltd.:** Estimated 6-8%
5. **Hengrui Medicine:** Estimated 5-7%

China National Medicines Corporation Ltd. holds a moderate market share compared to its competitors. The largest competitor, Sinopharm Group, dominates the market with a significant lead.

The moat of China National Medicines Corporation Ltd. is characterized by its established position in the medical supply and distribution sector. However, this advantage is less pronounced compared to leading companies like Sinopharm and Shanghai Pharmaceuticals. These companies benefit from larger networks, extensive resources, and a stronger international presence.

Overall, China National Medicines Corporation Ltd. has a certain moat, but it is relativized by strong competition. Competitors often have better economies of scale and broader product portfolios, giving them a potentially stronger moat.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 7.2% (2025)
**Market Share in the Healthcare Sector in China:** 12% (2025)

China National Medicines Corporation Ltd. has experienced solid revenue growth of 8.5% in recent years. This reflects the increasing demand for pharmaceutical products in China, driven by an aging population and growing health awareness.

The 7.2% profit growth demonstrates that the company is able to effectively manage its costs while benefiting from the revenue increase. The 12% market share in the Chinese healthcare sector highlights the company's strong market position.

The long-term growth prospects are positive as the healthcare industry in China continues to expand, and the company could benefit from government initiatives to improve healthcare. Analysts see potential in further market expansion and product diversification.

Overall, the stock could be a good investment, especially for investors interested in long-term growth opportunities in the Chinese healthcare sector.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Consistent payout over the last 5 years

China National Medicines Corporation Ltd. has regularly distributed dividends in recent years. The dividend yield is currently estimated at 2.5%, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payment is supported by the company's stable financial performance. Over the past five years, the company has consistently paid dividends, indicating a solid earnings position and a sustainable dividend policy. Analysts expect this practice to continue unless significant economic changes occur.